ERASCA INC (ERAS) Fundamental Analysis & Valuation

NASDAQ:ERAS • US29479A1088

Current stock price

16.31 USD
-0.7 (-4.12%)
At close:
16.59 USD
+0.28 (+1.72%)
After Hours:

This ERAS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ERAS Profitability Analysis

1.1 Basic Checks

  • ERAS had negative earnings in the past year.
  • ERAS had a negative operating cash flow in the past year.
  • ERAS had negative earnings in each of the past 5 years.
  • ERAS had a negative operating cash flow in each of the past 5 years.
ERAS Yearly Net Income VS EBIT VS OCF VS FCFERAS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -31.44%, ERAS is in the better half of the industry, outperforming 63.57% of the companies in the same industry.
  • ERAS has a better Return On Equity (-38.30%) than 69.19% of its industry peers.
Industry RankSector Rank
ROA -31.44%
ROE -38.3%
ROIC N/A
ROA(3y)-31.75%
ROA(5y)-33.38%
ROE(3y)-38.65%
ROE(5y)-40.36%
ROIC(3y)N/A
ROIC(5y)N/A
ERAS Yearly ROA, ROE, ROICERAS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ERAS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ERAS Yearly Profit, Operating, Gross MarginsERAS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. ERAS Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for ERAS has been increased compared to 1 year ago.
  • Compared to 5 years ago, ERAS has more shares outstanding
  • There is no outstanding debt for ERAS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ERAS Yearly Shares OutstandingERAS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
ERAS Yearly Total Debt VS Total AssetsERAS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • An Altman-Z score of 41.22 indicates that ERAS is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 41.22, ERAS belongs to the best of the industry, outperforming 94.57% of the companies in the same industry.
  • There is no outstanding debt for ERAS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 41.22
ROIC/WACCN/A
WACCN/A
ERAS Yearly LT Debt VS Equity VS FCFERAS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 10.04 indicates that ERAS has no problem at all paying its short term obligations.
  • ERAS's Current ratio of 10.04 is fine compared to the rest of the industry. ERAS outperforms 79.26% of its industry peers.
  • ERAS has a Quick Ratio of 10.04. This indicates that ERAS is financially healthy and has no problem in meeting its short term obligations.
  • ERAS has a Quick ratio of 10.04. This is in the better half of the industry: ERAS outperforms 79.46% of its industry peers.
Industry RankSector Rank
Current Ratio 10.04
Quick Ratio 10.04
ERAS Yearly Current Assets VS Current LiabilitesERAS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. ERAS Growth Analysis

3.1 Past

  • ERAS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.54%, which is quite impressive.
EPS 1Y (TTM)40.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ERAS is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -5.92% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-26.21%
EPS Next 2Y-10.38%
EPS Next 3Y-15.04%
EPS Next 5Y-5.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ERAS Yearly Revenue VS EstimatesERAS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
ERAS Yearly EPS VS EstimatesERAS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. ERAS Valuation Analysis

4.1 Price/Earnings Ratio

  • ERAS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ERAS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ERAS Price Earnings VS Forward Price EarningsERAS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ERAS Per share dataERAS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

  • ERAS's earnings are expected to decrease with -15.04% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.38%
EPS Next 3Y-15.04%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ERAS Dividend Analysis

5.1 Amount

  • No dividends for ERAS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ERAS Fundamentals: All Metrics, Ratios and Statistics

ERASCA INC

NASDAQ:ERAS (4/13/2026, 8:23:09 PM)

After market: 16.59 +0.28 (+1.72%)

16.31

-0.7 (-4.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners68.56%
Inst Owner Change0%
Ins Owners6.7%
Ins Owner Change0%
Market Cap5.07B
Revenue(TTM)N/A
Net Income(TTM)-124.55M
Analysts81.18
Price Target16.32 (0.06%)
Short Float %10.33%
Short Ratio4.93
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2%
Min EPS beat(2)-4.37%
Max EPS beat(2)8.37%
EPS beat(4)2
Avg EPS beat(4)2.87%
Min EPS beat(4)-6.95%
Max EPS beat(4)14.41%
EPS beat(8)4
Avg EPS beat(8)-0.98%
EPS beat(12)8
Avg EPS beat(12)5.06%
EPS beat(16)10
Avg EPS beat(16)-9.34%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)55.34%
PT rev (3m)227.27%
EPS NQ rev (1m)-90.91%
EPS NQ rev (3m)-87.5%
EPS NY rev (1m)-16.83%
EPS NY rev (3m)-17.72%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 15.59
P/tB 15.59
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)-0.56
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS0
BVpS1.05
TBVpS1.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.44%
ROE -38.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.75%
ROA(5y)-33.38%
ROE(3y)-38.65%
ROE(5y)-40.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.12%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.04
Quick Ratio 10.04
Altman-Z 41.22
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)17.75%
Cap/Depr(5y)391%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.09%
EPS Next Y-26.21%
EPS Next 2Y-10.38%
EPS Next 3Y-15.04%
EPS Next 5Y-5.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y13.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-30.25%
EBIT Next 3Y-15.83%
EBIT Next 5Y1.11%
FCF growth 1Y12.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.76%
OCF growth 3YN/A
OCF growth 5YN/A

ERASCA INC / ERAS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ERASCA INC?

ChartMill assigns a fundamental rating of 3 / 10 to ERAS.


What is the valuation status for ERAS stock?

ChartMill assigns a valuation rating of 0 / 10 to ERASCA INC (ERAS). This can be considered as Overvalued.


How profitable is ERASCA INC (ERAS) stock?

ERASCA INC (ERAS) has a profitability rating of 1 / 10.


Can you provide the financial health for ERAS stock?

The financial health rating of ERASCA INC (ERAS) is 8 / 10.